José Valentín
García Gutiérrez

Profesor/a Asociado/a en CC. de la Salud

Foto de José Valentín

Foto de Juan Luis

Juan Luis
Steegmann Olmedillas

Juan Luis Steegmann Olmedillas-rekin lankidetzan egindako argitalpenak (7)

2024

Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study
Annals of Hematology

2022

Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270

2021

Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
Blood Cancer Journal

2019

Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients
Annals of Hematology, Vol. 98, Núm. 2, pp. 321-330

2017

A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia
PLoS ONE, Vol. 12, Núm. 3

2016

Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting
Medicina Clinica, Vol. 146, Núm. 12, pp. 561.e1-561.e8
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
Leukemia, Vol. 30, Núm. 8, pp. 1648-1671